- Home
- SUI vs GMAB Comparison
SUI vs GMAB Comparison
Compare SUI & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUI
- GMAB
- Stock Information
- Founded
- SUI 1975
- GMAB 1999
- Country
- SUI United States
- GMAB Denmark
- Employees
- SUI N/A
- GMAB N/A
- Industry
- SUI Real Estate Investment Trusts
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SUI Real Estate
- GMAB Health Care
- Exchange
- SUI Nasdaq
- GMAB Nasdaq
- Market Cap
- SUI 15.5B
- GMAB 17.4B
- IPO Year
- SUI 1993
- GMAB N/A
- Fundamental
- Price
- SUI $129.66
- GMAB $31.32
- Analyst Decision
- SUI Buy
- GMAB Strong Buy
- Analyst Count
- SUI 12
- GMAB 6
- Target Price
- SUI $138.33
- GMAB $40.40
- AVG Volume (30 Days)
- SUI 679.3K
- GMAB 1.8M
- Earning Date
- SUI 10-29-2025
- GMAB 11-06-2025
- Dividend Yield
- SUI 3.21%
- GMAB N/A
- EPS Growth
- SUI 324.78
- GMAB 132.41
- EPS
- SUI 7.94
- GMAB 25.10
- Revenue
- SUI $3,236,900,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- SUI N/A
- GMAB $24.92
- Revenue Next Year
- SUI $4.73
- GMAB $15.97
- P/E Ratio
- SUI $16.32
- GMAB $1.25
- Revenue Growth
- SUI 32.39
- GMAB 29.57
- 52 Week Low
- SUI $109.22
- GMAB $17.24
- 52 Week High
- SUI $137.77
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- SUI 60.97
- GMAB 63.22
- Support Level
- SUI $124.81
- GMAB $29.98
- Resistance Level
- SUI $127.33
- GMAB $30.82
- Average True Range (ATR)
- SUI 1.97
- GMAB 0.65
- MACD
- SUI 0.42
- GMAB 0.15
- Stochastic Oscillator
- SUI 89.12
- GMAB 94.93
About SUI Sun Communities Inc.
Sun Communities is a residential REIT that focuses on owning manufactured housing and residential vehicle communities. The company currently owns a portfolio of 501 properties, which includes 337 manufactured housing communities and 164 residential vehicle communities. Sun targets owning properties that are desirable as second homes or vacation properties with nearly 50% of the portfolio located in either Florida or Michigan near major bodies of water.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.